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Abstract (250/250) 
Objectives: We report 2-year results from CheckMate 141 to establish the long-term efficacy 
and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with 
recurrent or metastatic (R/M), platinum-refractory squamous cell carcinoma of the head and 
neck (SCCHN). 
Methods: Patients with R/M SCCHN with tumor progression/recurrence within 6 months of 
platinum therapy were randomized 2:1 to nivolumab 3 mg/kg every 2 weeks or investigator’s 
choice (IC). Primary endpoint: overall survival (OS). Data cutoff: September 2017.  
Results: With 24.2 months’ minimum follow-up, nivolumab (n = 240) continued to improve OS 
vs IC (n = 121), hazard ratio (HR) = 0.68 (95% CI 0.54–0.86). Nivolumab nearly tripled the 
estimated 24-month OS rate (16.9%) vs IC (6.0%), and demonstrated OS benefit across 
patients with tumor PD-L1 expression ≥1% (HR [95% CI] = 0.55 [0.39–0.78]) and <1% (HR 
[95% CI] = 0.73 [0.49–1.09]), and regardless of tumor HPV status. Estimated OS rates at 18, 
24, and 30 months with nivolumab were consistent irrespective of PD-L1 expression 
(<1%/≥1%). In the nivolumab arm, there were no observed differences in baseline 
characteristics or safety profile between long-term survivors and the overall population. Grade 
3–4 treatment-related adverse event rates were 15.3% and 36.9% for nivolumab and IC, 
respectively.  
Conclusion: Nivolumab significantly improved OS at the primary analysis and demonstrated 
prolonged OS benefit vs IC and maintenance of a manageable and consistent safety profile with 
2-year follow-up. OS benefit was observed with nivolumab irrespective of PD-L1 expression and 
HPV status. (Clinicaltrials.gov: NCT02105636) 
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Keywords (MeSH terms):  
Nivolumab • Head and Neck Neoplasms • Carcinoma, squamous cell of head and neck • 
Immunotherapy • Papillomaviridae (Hpv, Human Papillomavirus Viruses) • Programmed Cell 
Death 1 Receptor • CD274 protein, human (PD-L1 Protein, Human) • Clinical Trial, Phase III • 
Survival Analysis • Survivors (Long-term Survivors) 
 
Highlights:  
 Nivolumab showed prolonged OS benefit in patients with R/M SCCHN post-platinum  
 Long-term OS benefit was observed irrespective of PD-L1 expression or HPV status 
 No new safety concerns were identified from long-term nivolumab treatment 
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Introduction 
Squamous cell carcinoma of the head and neck (SCCHN) includes neoplasms in the oral cavity, 
pharynx, and larynx, and accounts for 90% of all head and neck cancers [1-3]. Patients with 
recurrent/metastatic (R/M) SCCHN who progress within 6 months after platinum-based therapy 
have poor long-term prognosis and limited treatment options, with a median overall survival 
(OS) of ≤6 months [4, 5].   
CheckMate 141 evaluated the efficacy, safety, and patient-reported quality of life of 
nivolumab monotherapy vs standard single agent of investigator’s choice (IC) in patients with 
R/M SCCHN who experienced tumor progression or recurrence within 6 months of platinum-
based therapy administered in the adjuvant, primary (ie, with radiation), recurrent, or metastatic 
setting [6, 7]. Nivolumab is the only immunotherapy to significantly improve OS at the primary 
analysis in this patient population, hazard ratio (HR) vs IC = 0.70 (97.73% confidence interval 
[CI] 0.51–0.96); p = 0.01 [6]. With 1-year follow-up, nivolumab continued to improve OS 
compared with IC; HR = 0.71 (95% confidence interval [CI]: 0.55, 0.90) [8]. The Kaplan-Meier–
estimated 18-month OS rate with nivolumab was nearly triple that with IC (21.5% vs 8.3%). The 
objective response rate (ORR) with nivolumab was more than twice that of IC (13.3% vs 5.8%). 
The safety profile of nivolumab was manageable, with fewer grade 3–4 treatment-related 
adverse events (TRAEs) compared with IC. Nivolumab also stabilized quality-of-life measures, 
whereas clinically meaningful deterioration was observed with IC [7]. Here, we report long-term 
(2-year) follow-up of CheckMate 141 in the overall population, as well as in subgroups defined 
by baseline tumor programmed death ligand 1 (PD-L1) expression and human papillomavirus 
(HPV) status. 
 
Patients and methods 
Study design and patients  
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CheckMate 141 is a randomized, open-label, phase 3 trial (NCT02105636), the detailed study 
design of which has been described previously [6]. Briefly, eligible patients were 18 years of age 
or older, had histologically confirmed R/M SCCHN of the oral cavity, oropharynx, hypopharynx, 
or larynx, and had tumor progression on or within 6 months after the last dose of platinum-
based chemotherapy administered in the locally advanced, recurrent, or metastatic disease 
setting. Patients were randomized 2:1, stratified by prior cetuximab treatment, to receive 
nivolumab (3 mg/kg every 2 weeks) or standard single agent of IC (methotrexate 40–60 mg/m2 
weekly, docetaxel 30–40 mg/m2 weekly, or cetuximab 400 mg/m2 once, then 250 mg/m2 
weekly). Treatment continued until tumor progression or unacceptable toxicity. Patients in the 
nivolumab arm were allowed to continue nivolumab treatment beyond tumor progression if they 
met predefined, protocol-specified criteria [9]. 
CheckMate 141 was conducted in accordance with the ethical principles in the 
Declaration of Helsinki. All patients provided written informed consent prior to enrollment. The 
study was approved by the institutional review board or independent ethics committee at each 
center and was conducted in accordance with Good Clinical Practice guidelines defined by the 
International Conference on Harmonisation. 
 
Outcomes 
 
The primary endpoint was OS, defined as the time from randomization to death due to any 
cause. Secondary endpoints included progression-free survival (PFS) and ORR. Tumor 
responses were evaluated every 6 weeks from week 9 until progression or treatment 
discontinuation using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 [10]. Safety 
was evaluated using the Common Terminology Criteria for Adverse Events, version 4.0. 
Adverse events with potential immunologic cause were classified as select adverse events. 
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Exploratory biomarker analyses 
 
Fresh or archival pretreatment tumor specimens were obtained after the last therapy and prior 
to trial entry. Tumor PD-L1 membrane expression was evaluated centrally by 
immunohistochemical testing using the Dako PD-L1 IHC 28-8 pharmDx assay in a minimum of 
100 evaluable tumor cells. Patients were defined as PD-L1 expressors if their tumor had ≥1% 
PD-L1 expression and non-expressors if their tumor had <1% PD-L1 expression. Documented 
tumor HPV status, assessed by p16 immunohistochemical testing by local or central analysis, 
was required for patients with oropharyngeal cancer. Tumors were defined as HPV positive if 
diffuse staining was present in at least 70% of tumor cells.  
 
Statistical analyses 
 
The current analyses are based on a September 2017 data cutoff, representing a minimum 
follow-up of 24.2 months. Efficacy analyses were conducted in all randomized patients (intent-
to-treat [ITT] population), and safety analyses were conducted in all treated patients. 
OS and PFS were assessed using the Kaplan-Meier method, and HRs and 
corresponding 2-sided 95% CIs were estimated using a Cox proportional hazards model. A 
generalization of the Brookmeyer and Crowley method was used to compute CIs for median 
survival times, and a 2-sided Cochran-Mantel-Haenszel test was used to compute the odds ratio 
and associated CIs for tumor response. 
 
Results 
 
Patients 
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Baseline characteristics of the 361 randomized patients have been described previously [6]. 
Compared with the original analysis [6], baseline tumor PD-L1 expression and HPV status were 
quantifiable in 15 and 8 additional patients, respectively (Table 1). At the time of this analysis, 8 
(3.4%) patients remained on treatment in the nivolumab arm compared with 0 in the IC arm 
(Supplementary Table 1 and Supplementary Fig. 1). Sixteen patients in the nivolumab arm 
discontinued treatment between 1 and 2 years, most commonly due to disease progression (n = 
8); 2 patients discontinued nivolumab therapy after 2 years (1 each due to adverse events 
unrelated to study drug and patient request). No patient discontinued nivolumab therapy after 2 
years due to disease progression or treatment-related toxicity. The median (range) duration of 
treatment was 1.9 (0 to 36+) months for nivolumab and 1.9 (0 to 13) months for IC. After 
treatment discontinuation, 5.3% of patients in the nivolumab arm and 10.1% of patients in the IC 
arm received subsequent immunotherapy (nivolumab, pembrolizumab, durvalumab, or 
urelumab) (Supplementary Table 2).  
 
Efficacy in overall study population 
 
Consistent with the primary analysis, nivolumab demonstrated sustained OS benefit compared 
with IC, with a 32% reduction in risk of death; HR = 0.68 (95% CI 0.54–0.86) with long-term 
follow-up (minimum 24.2 months). Median (95% CI) OS was 7.7 (5.7–8.8) months in the 
nivolumab arm and 5.1 (4.0–6.2) months in the IC arm (Fig. 1). The Kaplan-Meier–estimated 
24-month OS rate with nivolumab (16.9% [95% CI 12.4%–22.0%]) was nearly triple that of IC 
(6.0% [95% CI 2.7%–11.3%]). The estimates of the HR for death among prespecified 
demographic and clinical subgroups, including age, Eastern Cooperative Oncology Group 
(ECOG) performance status, tumor site, and prior lines of systemic therapy, were generally 
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consistent with the ITT population, favoring nivolumab (Supplementary Fig. 2). With longer 
follow-up, PFS (HR = 0.87 [95% CI 0.68–1.11]) was similar to previous analyses [6, 8].  
The ORR was unchanged from previous analyses (Table 2) [6, 8]. In the nivolumab arm, 
7 complete responses were observed, including 1 patient who had a partial response at the 
previous analysis, but since then converted to a complete response. The median (range) time to 
response remained unchanged in both treatment arms from previous follow-ups, 2.1 (1.8 to 7.4) 
months for nivolumab vs 2.0 (1.9 to 4.6) months for IC [6]. The median (range) duration of 
response with nivolumab treatment was more than double that with IC (9.7 [2.8 to 32.8+] vs 4.0 
[1.5+ to 11.3]). 
 
Tumor PD-L1 expression and HPV status  
 
OS benefit with nivolumab vs IC was demonstrated across PD-L1 expressors and non-
expressors (Fig. 2). With long-term follow-up, nivolumab continued to provide OS benefit in PD-
L1 expressors, with a consistent 45% reduction in the risk of death compared with IC (HR = 
0.55 [95% CI 0.39–0.78]) (Fig. 2A). In PD-L1 non-expressors, nivolumab demonstrated a 27% 
reduction in the risk of death compared with IC (HR = 0.73 [95% CI 0.49–1.09] (Fig. 2B). For 
these patients, HR (95% CI) trended lower as follow-up time increased: 0.83 (0.54–1.29) and 
0.89 (0.54–1.45) at the 1-year (September 2016 data cutoff, Supplementary Fig 3A) and primary 
analysis (December 2015 data cutoff, Supplementary Fig. 3B) [6], respectively. Kaplan-Meier 
estimated OS rates with nivolumab were consistent between PD-L1 expressors and non-
expressors at 18 (24.0% and 26.2%, respectively), 24 (18.5% and 20.7%), and 30 (13.7% and 
11.2%) months (Fig. 2). Median PFS for nivolumab was similar across PD-L1 subgroups and 
was not differentiated from IC in either subgroup, 2.1 (95% CI 2.0–3.4) months and 2.0 (95% CI 
1.9–2.1) months in PD-L1 expressors and non-expressors, respectively, in the nivolumab arm, 
and 2.0 (95% CI 1.9–3.1) months and 2.7 (95% CI 2.0–4.6) months in PD-L1 expressors and 
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non-expressors in the IC arm. The HR for PFS was 0.59 (95% CI 0.41–0.84) in PD-L1 
expressors and 1.13 (95% CI 0.75–1.71) in PD-L1 non-expressors. Nivolumab improved ORR 
compared with IC in PD-L1 expressors; ORR was similar across treatment arms in PD-L1 non-
expressors (Supplementary Table 3). Complete responses were observed across PD-L1 
expressors (n = 2), non-expressors (n = 2), and PD-L1 non-quantifiable (n = 3). 
OS benefit with nivolumab was observed in both patients with HPV-positive and HPV-
negative tumors, and benefit was maintained with long-term (2-year) follow-up (Fig. 3). 
Nivolumab demonstrated approximately 40% reduction in the risk of death compared with IC in 
both the HPV-positive subgroup (HR = 0.60 [95% CI 0.37–0.97]) as well as the HPV-negative 
subgroup (HR = 0.59 [95% CI 0.38–0.92]). Nivolumab improved ORR compared with IC in 
patients with HPV-positive tumors; ORR was similar across treatment arms in patients with 
HPV-negative tumors (Supplementary Table 3).   
Overall survival was further analyzed in subgroups defined according to both tumor HPV 
status and PD-L1 expression (Supplementary Fig. 4). Nivolumab prolonged median OS vs IC in 
each of the 4 subgroups, with the greatest benefit (HR = 0.39 [95% CI 0.18–0.81]) found among 
PD-L1 expressors with HPV-positive tumors. The results of this analysis should be interpreted 
with caution, as sample sizes and power were limited. 
 
Safety 
 
Among all treated patients (n = 347), nivolumab demonstrated a favorable safety profile 
compared with IC with long-term follow-up. The safety profile remained manageable and 
consistent with previous analyses [6, 8], with fewer grade 3–4 TRAEs in the nivolumab arm 
compared with the IC arm (Table 3). Most grade 3–4 TRAEs occurred within the first 6 months 
of initiating treatment; 19.5%, 2.5%, and 1.7% of patients in the nivolumab arm experienced 
grade 3–4 TRAEs within the first 6 months, between 6 and 12 months, and at or after 12 months 
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of initiating study treatment, respectively. There were 6 patients with grade 3 TRAEs first 
occurring after 12 months of initiating therapy; 4 in the nivolumab arm (hyperlipasemia and 
hyperamylasemia; hyponatremia; deterioration of diabetes mellitus; and lipase increased and 
weight decreased), and 2 patients in the IC arm (hypothyroidism and increased aspartate 
aminotransferase); no patients experienced grade 4 TRAEs during this time frame. The most 
common select TRAEs in the nivolumab and IC arms were skin-related and gastrointestinal, 
respectively (Table 3). The incidence of serious TRAEs was lower in the nivolumab arm (7.2%) 
compared with the IC arm (15.3%). A greater proportion of patients in the IC arm compared with 
the nivolumab arm discontinued the study due to TRAEs at any time (9.0% vs 4.2%). Four 
TRAEs led to discontinuation between 1 and 2 years in the nivolumab arm: nephritis; 
pneumonitis; uncontrollable diabetes mellitus, chronic heart failure, and fatigue; and lipase 
elevation with progressive weight loss (n = 1 each). The number of treatment-related deaths 
remained unchanged from the primary analysis [6], (2 deaths in the nivolumab arm [1 each due 
to pneumonitis and hypercalcemia], and 1 death in the IC arm due to treatment-related lung 
infection).  
 
Post hoc analysis of 2-year survivors 
 
In the nivolumab arm, 37 patients (15.4%) were alive (in survival follow-up) at 2 years. There 
were no observed differences in baseline demographic or disease characteristics among 
patients in the nivolumab arm who were alive at 2 years compared with the nivolumab ITT 
population (Table 4). The safety profile of 2-year survivors in the nivolumab arm was consistent 
with all nivolumab-treated patients (Supplementary Table 4); however, a relatively higher rate of 
any-grade TRAEs was reported in 2-year survivors (89.2%) vs in all nivolumab-treated patients 
(61.9%). Fatigue was the most common TRAE among all nivolumab-treated patients and 2-year 
survivors. Disease progression was the most frequent primary cause of death in both study 
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arms, both among patients who experienced late death (>24 months after the first dose) and 
those who experienced early death.  
 
DISCUSSION 
With long-term (minimum 2-year) follow-up, nivolumab demonstrated prolonged OS benefit 
compared with IC and maintained a favorable safety profile in patients with R/M SCCHN post–
platinum therapy. At the time of the current analysis, there were 8 patients (3.4%) continuing on 
nivolumab treatment and no patients continuing on IC.  
Nivolumab is the only immunotherapy to demonstrate OS benefit across PD-L1 
expressors/non-expressors in this patient population. Notably, Kaplan-Meier–estimated OS 
rates at 18, 24, and 30 months among nivolumab patients were consistent between PD-L1 
expressors and non-expressors. Among PD-L1 expressors, OS benefit vs IC was observed at 
the primary analysis [6] and maintained at the 2-year follow-up. Among PD-L1 non-expressors, 
the HR for death consistently trended lower as follow-up time increased, suggesting a long-term 
benefit of nivolumab in this patient population. An assessment of the patients who had tumor 
PD-L1 data at the time of the primary analysis (excluding additional patients with quantifiable 
PD-L1 expression since the primary analysis) resulted in a HR of 0.77 (95% CI 0.51–1.15). In 
addition to the OS benefit seen, complete responses were observed across PD-L1 
expressors/non-expressors. 
Both patients with HPV-positive and HPV-negative tumors benefited from nivolumab 
therapy, and this was maintained with long-term follow-up. Notably, with current follow-up, 
Kaplan-Meier OS curves were similar between both HPV subgroups, and the HRs were nearly 
identical. Given the worse prognosis historically seen among patients with HPV-negative 
SCCHN [11], nivolumab helps address the unmet medical need in this population.  
The median duration of response in the current analysis for each arm was similar to that 
of 1 year; however, the upper limit of the range for nivolumab arm continued to increase, further 
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suggesting that patients who remained on nivolumab continued to experience long-term benefit. 
Importantly, the OS benefit was seen despite ~10% of patients in the IC arm receiving 
subsequent immunotherapy, reinforcing the significance of the OS results.  
There were no observed differences in baseline characteristics, including tumor PD-L1 
expression and HPV status, among nivolumab-treated patients who were alive at 2 years 
compared with the nivolumab ITT population. Similarly, the safety profile of patients alive at 2 
years in the nivolumab arm was consistent with all nivolumab-treated patients; this lack of new 
safety signals with long-term follow-up suggests a predictable safety profile. The slightly higher 
rate of any-grade TRAEs among 2-year survivors compared with all treated patients was likely 
due to these patients having longer follow-up, and thus having more time to experience TRAEs.  
In CheckMate 141, nivolumab was dosed according to a weight-based regimen (3 mg/kg 
every 2 weeks), which was also the initial approved regimen in the United States and other 
countries. Recently, however, a flat dose of 240 mg every 2 weeks or 480 mg every 4 weeks via 
30-minute intravenous infusion was approved in the United States [12]. The 240 mg every 2 
week dosing regimen was also recently recommended by the Committee for Medicinal Products 
for Human Use of the European Medicines Agency [13]. This added flexibility in dosing could 
decrease the burden of healthcare visits for patients and caregivers.  
 
 
Conclusion 
Nivolumab is an established therapeutic option in R/M SCCHN post-platinum therapy and the 
only immunotherapy to demonstrate significant OS improvement in the primary analysis of a 
phase 3 study (CheckMate 141). Nivolumab is also the only immunotherapy to stabilize QoL in 
this patient population. With long-term follow-up, nivolumab demonstrated prolonged OS benefit 
compared with IC (methotrexate, docetaxel, or cetuximab) and maintained a favorable safety 
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profile, with no new safety signals identified. Nivolumab demonstrated OS benefit across PD-L1 
expressors/non-expressors and irrespective of HPV status in this patient population 
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TABLES 
Table 1 
Baseline tumor PD-L1 expression and HPV status. 
Patients, n (%) Nivolumab (n = 240) IC (n = 121) 
Tumor PD-L1 expression  
  
Non-expressors (<1%) 76 (31.7) 40 (33.1) 
Expressors (≥1%) 96 (40.0) 63 (52.1) 
Not quantifiable 68 (28.3) 18 (14.9) 
Tumor HPV status 
  
Positive 64 (26.7) 29 (24.0) 
Negative 56 (23.3) 37 (30.6) 
Unknown/not reported 120 (50.0) 55 (45.5) 
IC, investigator’s choice; HPV, human papillomavirus; PD-L1, programmed death ligand 1. 
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Table 2 
Best overall response. 
 
Nivolumab  
(n = 240) 
IC  
(n = 121) 
Best overall response, n (%)   
Complete response 7 (2.9) 1 (0.8) 
Partial response 25 (10.4) 6 (5.0) 
Stable disease 55 (22.9) 43 (35.5) 
Progressive disease 99 (41.3) 42 (34.7) 
Unable to determine  54 (22.5) 29 (24.0) 
ORR, % (95% CI)  13.3 (9.3–18.3) 5.8 (2.4–11.6) 
Time to response, median (range), 
mo 
2.1 (1.8–7.4) 2.0 (1.9–4.6) 
Duration of response, median 
(range), mo 
9.7 (2.8 to 32.8+) 4.0 (1.5+ to 11.3) 
CI, confidence interval; IC, investigator’s choice; ORR, objective response rate. 
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Table 3 
Most common TRAEs (≥15% in any arm) and select TRAEs among all treated patients.  
Patients, n (%) Nivolumab (n = 236) IC (n = 111) 
Any grade Grade 3–4 Any grade Grade 3–4 
Any TRAE 146 (61.9) 36 (15.3) 88 (79.3) 41 (36.9) 
TRAEs in ≥15% of patients     
Fatigue 37 (15.7) 5 (2.1) 20 (18.0) 3 (2.7) 
Nausea 22 (9.3) 0 23 (20.7) 1 (0.9) 
Anemia 12 (5.1) 3 (1.3) 19 (17.1) 6 (5.4) 
Asthenia 10 (4.2) 1 (0.4) 17 (15.3) 2 (1.8) 
Select TRAEs     
Skin 41 (17.4) 0 14 (12.6) 2 (1.8) 
Endocrine 22 (9.3) 1 (0.4) 1 (0.9) 0 
Gastrointestinal 20 (8.5) 1 (0.4) 16 (14.4) 2 (1.8) 
Hepatic 7 (3.0) 2 (0.8) 5 (4.5) 1 (0.9) 
Pulmonary 7 (3.0) 2 (0.8) 1 (0.9) 0 
Hypersensitivity/infusion reactions 3 (1.3) 0 2 (1.8) 1 (0.9) 
Renal 3 (1.3) 0 2 (1.8) 1 (0.9) 
IC, investigator’s choice; TRAEs, treatment-related adverse events. 
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Table 4 
Baseline characteristics in the nivolumab arm among the ITT population and 2-year survivors. 
Patients, n (%) 
Nivolumab 
ITT 
(n = 240) 
2-year survivors 
(n = 37) 
ECOG performance status 
 
 
0 49 (20.4) 10 (27.0) 
≥1 190 (79.2) 27 (73.0) 
Not reported 1 (0.4) 0 
Tobacco use   
Current/former 191 (79.6) 31 (83.8) 
Never 39 (16.3) 6 (16.2) 
Unknown 10 (4.2) 0 
Prior cetuximab use   
Yes 147 (61.3) 19 (51.4) 
No 93 (38.8) 18 (48.6) 
Number of lines of prior systemic 
therapy 
  
1 106 (44.2) 14 (37.8) 
2 80 (33.3) 16 (43.2) 
≥3 54 (22.5) 7 (18.9) 
Site of primary tumor   
Oral cavity 108 (45.0) 13 (35.1) 
Pharynx 92 (38.3) 17 (45.9) 
Larynx 34 (14.2) 5 (13.5) 
Other 6 (2.5) 2 (5.4) 
Tumor PD-L1 expression   
Expressors (≥1%) 96 (40.0) 16 (43.2) 
Non-expressors (<1%) 76 (31.7) 15 (40.5) 
Tumor HPV status   
Positive 64 (26.7) 12 (32.4) 
Negative 56 (23.3) 13 (35.1) 
Unknown/not reported 120 (50.0) 12 (32.4) 
ECOG, Eastern Cooperative Oncology Group; HPV, human papillomavirus; ITT, intent-to-treat; PD-L1, programmed 
death ligand 1.  
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FIGURES 
 
Fig. 1. Overall survival (OS) with a minimum follow-up of 24.2 months (intent-to-treat 
population). Symbols represent censored observations; dotted lines indicate OS rate time 
points. CI, confidence interval; HR, hazard ratio; IC, investigator’s choice; Nivo, nivolumab. 
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Fig. 2. Overall survival (OS) in programmed death ligand 1 (PD-L1) expressors (A) and PD-L1 
non-expressors (B). Symbols represent censored observations. CI, confidence interval; HR, 
hazard ratio; IC, investigator’s choice; Nivo, nivolumab.  
 
  
Final Draft       Ferris, et al. Oral Oncol  HIGHLY CONFIDENTIAL 
Fig. 3. Overall survival (OS) by tumor human papillomavirus (HPV) status, positive (A) and 
negative (B). Symbols represent censored observations. CI, confidence interval; HR, hazard 
ratio; IC, investigator’s choice; Nivo, nivolumab. 
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Supplementary Table 1 
Patient disposition. 
Patients, n (%) 
Nivolumab  
(n = 236) 
IC 
(n = 111) 
Continuing treatment 8 (3.4) 0 
Not continuing treatment 
Disease progression 
AE unrelated to study drug 
Study drug toxicity 
Patient request to discontinue/withdrawal of consent 
Othera 
228 (96.6) 
182 (77.1) 
19 (8.1) 
12 (5.1) 
12 (5.1) 
3 (1.3) 
111 (100.0) 
87 (78.4) 
3 (2.7) 
10 (9.0) 
7 (6.3) 
4 (3.6) 
a
 Other includes loss to follow-up, poor/noncompliance, maximum clinical benefit, and patient no longer meeting 
study criteria. 
AE, adverse event; IC, investigator’s choice. 
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Supplementary Table 2.  
Subsequent therapies. 
 
Patients, n (%) 
Nivolumab 
(n = 228) 
IC 
(n = 109) 
Any subsequent therapya 91 (39.9) 43 (39.4) 
Radiotherapy 30 (13.2) 14 (12.8) 
Surgery 2 (0.9) 3 (2.8) 
Systemic therapy 82 (36.0) 36 (33.0) 
Monoclonal antibodyb 31 (13.6) 8 (7.3) 
Taxane 35 (15.4) 11 (10.1) 
Other – approved agent 31 (13.6) 12 (11.0) 
Folic acid analog 22 (9.6) 7 (6.4) 
Platinum-based chemotherapy 16 (7.0) 11 (10.1) 
Other – experimental agent 15 (6.6) 3 (2.8) 
Immunotherapyc  12 (5.3) 11 (10.1) 
PD-1/PD-L1 inhibitors 9 (3.9) 10 (9.2) 
Unassigned 1 (0.4) 0 
a 
Patients may have received more than 1 type of subsequent therapy, which was defined as non-study anti-cancer 
therapy started on or after first dosing date (or randomization date, if patient was not treated). 
b 
Bevacizumab, cetuximab. 
c 
Nivolumab, pembrolizumab, durvalumab, urelumab. 
IC, investigator’s choice; PD-1, programmed death 1; PD-L1 programmed death ligand 1. 
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Supplementary Table 3 
Best overall response by tumor PD-L1 expression and HPV status. 
ORR, % (95% CI) Nivolumab  IC  
PD-L1 expressors 
 
PD-L1 non-expressors 
 
17.7 (10.7–26.8) 
[n = 96] 
11.8 (5.6–21.3) 
[n = 76] 
1.6 (0.04–8.5) 
[n = 63] 
12.5 (4.2–26.8) 
[n = 40] 
HPV-positive 
 
HPV-negative 
 
17.2 (8.9–28.7) 
[n = 64] 
14.3 (6.4–26.2) 
[n = 56] 
3.4 (0.1–17.8) 
[n = 29] 
10.8 (3.0–25.4) 
 [n = 37] 
CI, confidence interval; HPV, human papillomavirus; IC, investigator’s choice; ORR, objective response rate; PD-L1, 
programmed death ligand 1. 
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Supplementary Table 4 
TRAEs in ≥10% of all nivolumab-treated patients or nivolumab 2-year survivors. 
  Patients 
Nivolumab 
All treated (n = 236) 2-year survivors (n = 37) 
Any grade Grade 3–4 Any grade Grade 3–4 
Any TRAE, n (%) 146 (61.9) 36 (15.3) 33 (89.2) 10 (27.0) 
Fatigue 37 (15.7) 5 (2.1) 10 (27.0) 1 (2.7) 
Nausea 22 (9.3) 0 7 (18.9) 0 
Diarrhea 20 (8.5) 1 (0.4) 5 (13.5) 0 
Pruritus 19 (8.1) 0 6 (16.2) 0 
Rash 19 (8.1) 0 8 (21.6) 0 
Decreased appetite 19 (8.1) 0 5 (13.5) 0 
Hypothyroidism 14 (5.9) 0 4 (10.8) 0 
Asthenia 10 (4.2) 1 (0.4) 4 (10.8) 0 
Lipase increased 9 (3.8) 6 (2.5) 4 (10.8) 3 (8.1) 
Amylase increased 8 (3.4) 3 (1.3) 4 (10.8) 2 (5.4) 
Cough 7 (3.0) 1 (0.4) 4 (10.8) 0 
Hypertension 6 (2.5) 1 (0.4) 4 (10.8) 1 (2.7) 
TRAEs, treatment-related adverse events.
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Supplementary Fig. 1. CONSORT diagram (minimum follow-up, 24.2 months).  
HPV, human papillomavirus; PD-L1, programmed death ligand 1. 
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Supplementary Fig. 2. Treatment effect on overall survival, according to baseline subgroups.  
 
a
 Stratification factor. 
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; IC, investigator’s choice; 
Nivo, nivolumab.   
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Supplementary Fig. 3. Overall survival in PD-L1 non-expressors at the 1-year follow-up (A) 
and primary analysis (B).  .
 
Symbols represent censored observations 
CI, confidence interval; HR, hazard ratio; IC, investigator’s choice; Nivo, nivolumab; OS, overall survival; PD-L1, 
programmed death ligand 1. 
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Supplementary Fig. 4. Treatment effect on overall survival by tumor PD-L1 expression and 
HPV status. 
 
CI, confidence interval; HPV, human papillomavirus; HR, hazard ratio; IC, investigator’s choice; Nivo, nivolumab; 
PD-L1, programmed death ligand 1. 
 
 
